Traders should monitor upcoming clinical data readouts in late 2026, which could serve as a major value inflection point. The combination strategy with BBO-10203 may enhance therapeutic potential and commercial reach in RAS-driven cancers.
Price Chart
Executive Summary
BBOT announced preclinical and early clinical data for BBO-11818, a novel panKRAS inhibitor showing potent activity against multiple KRAS mutants, including G12D and G12V, with a confirmed partial response in pancreatic cancer. The company plans to release additional Phase 1 data in late 2026 and initiate combination studies with its RAS:PI3Kα breaker BBO-10203.
Key Facts
- BBO-11818 is a selective, orally bioavailable non-covalent panKRAS inhibitor targeting both ON and OFF states of KRAS.
- Preclinical data show strong activity in KRASG12D, KRASG12V, and KRASG12C models with >500-fold selectivity over HRAS/NRAS.
- Phase 1 KONQUER-101 trial showed a confirmed partial response with 56% tumor reduction in a pancreatic cancer patient.
- Additional clinical data expected in the second half of 2026; combination trial with BBO-10203 to begin later in 2026.
- Published in peer-reviewed journal Cancer Discovery, highlighting scientific validation.
Financial Impact
No direct financial figures disclosed; potential long-term revenue upside if BBO-11818 advances successfully through clinical development.
Risk Factors
- Clinical development risk: Early-phase data may not translate into later-stage success.
- Competition from other KRAS inhibitors in development, particularly those targeting G12D.
- Dilution risk if future capital raises are needed to fund advanced trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251118 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 6w ago | EFFECT | $4.95 $3.31 | ▲ +33.13% | ▲ +35.00% | $2.64 (+46.67%) |
Sep 9, 2026 6w ago | EFFECT | $6.76 $3.44 | ▼ −49.07% | ▼ −51.27% | $2.64 (−60.92%) |
Aug 15, 2026 10w ago | Institutional Cluster | $9.04 $4.88 | ▲ +46.02% | ▲ +44.04% | $2.64 (+70.80%) |
Aug 11, 2026 10w ago | Press Release | $9.42 $5.52 | ▼ −41.40% | ▼ −39.50% | $2.64 (−71.97%) |
Jun 22, 2026 18w ago | 8-K | $7.50 $8.42 | ▲ +12.27% | ▲ +11.11% | $2.64 (−64.80%) |
May 12, 2026 23w ago | Press Release | $8.08 $7.46 | ▼ −7.67% | ▼ −7.06% | $2.64 (−67.33%) |
Apr 21, 2026 26w ago | Press Release | $8.87 $8.72 | ▼ −1.69% | ▼ −4.86% | $2.64 (−70.24%) |
Apr 20, 2026 27w ago | Press Release | $9.46 $8.75 | ▼ −7.51% | ▼ −12.42% | $2.64 (−72.09%) |
Mar 6, 2026 33w ago | Press Release | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.64 (−74.66%) |
Mar 5, 2026 33w ago | 8-K | $10.42 $8.91 | ▼ −14.49% | ▼ −12.45% | $2.64 (−74.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers